2022
Ovarian cancer risk-reduction and screening in BRCA 1/2 mutation carriers (383)
DiSilvestro J, Dexter J, Haddad J, Beffa L, Raker C, Laprise J, Wilbur J, Clark M, Bradford L, Brown A, Hofstatter E, Dalela D, Toland M, Robison K, Stuckey A. Ovarian cancer risk-reduction and screening in BRCA 1/2 mutation carriers (383). Gynecologic Oncology 2022, 166: s195-s196. DOI: 10.1016/s0090-8258(22)01605-5.Peer-Reviewed Original ResearchFemale BRCA mutation carriersOral contraceptive pillsOvarian cancer screeningBRCA mutation carriersOvarian cancerMutation carriersGenetic testingGynecologic oncologistsContraceptive pillsCancer screeningExact testBRCA 1/2 mutation carriersCombined oral contraceptive pillBRCA mutation typeRisk-reducing surgeryPrimary care providersHigh-risk populationHalf of womenBRCA1/2 mutation carriersPossible early detectionFisher's exact testCross-sectional surveyGenetic counselorsCA 125Surgical options
2013
State of the Art in Imaging and Chemoprevention for High-Risk Patients
Hofstatter E, Andrejeva L, Chagpar A. State of the Art in Imaging and Chemoprevention for High-Risk Patients. Current Breast Cancer Reports 2013, 5: 125-133. DOI: 10.1007/s12609-013-0104-1.Peer-Reviewed Original ResearchBreast cancer preventionCancer preventionBreast cancerAccurate breast cancer risk assessmentAppropriate breast cancer screeningBreast cancer risk assessmentChemoprevention clinical trialsHigh-risk patientsBreast cancer screeningPromising new optionCancer risk assessmentCancer screeningClinical trialsPractical updatePatientsEarly detectionCancerPreventionNew optionsRiskRisk assessmentChemopreventionOptionsBreastClinicians